ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/chemcomm

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Formal [3+2] Cycloaddition of 1-Cyanocyclopropane 1-Ester with Pyridine, Quinoline or Isoquinoline: General and Efficient Strategy for Construction of Cyanoindolizine Skeletons

Juanjuan Liu, Lanxiang Zhou, Weijian Ye, and Cunde Wang*

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX
DOI: 10.1039/b000000x

An efficient and straightforward synthetic protocol has been developed for the preparation of cyanoindolizine derivatives via a cycloaddition reaction between 1-cyanocyclopropane 1-ester and pyridine or benzopyridine for the generation of a wide range of structurally interesting and pharmacologically significant compounds.

Indolizines are important classes of organic compounds that are not only widely used as synthetic building blocks and various kinds of functional materials,[1] but they also occur in numerous natural products and pharmaceuticals as privileged scaffolds.[2] Among them, the cyanoindolizines have attracted more attention recently. Cyanoindolizine derivatives were investigated extensively as highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase,[3] a xanthine oxidase inhibitory activities for the prevention or treatment of a disease associated with abnormal serum uric acid level,[4] anticancer agents,[2,5] potent inhibitors of *Acinetobacter baumannii* OXA-24 carbapenemase,[6] anti-inflammatory, and antimalarial agents.[7]

The synthesis of indolizine derivatives has made much progress,[8] most traditionally synthetic strategies require starting from pyridinium N-methylides [8b,9] or pyridines with specific C2 functionalization.[10] In contrast, only some annulation reactions of the pyridine ring that involve [3+2] cycloaddition have recently been reported.[11,12] In recent years, some previous studies revealed donor-acceptor cyclopropanes are versatile building blocks in Lewis acid-promoted formal cycloadditions for the construction of various cyclic skeletons.[13] The formal [3+2] cycloaddition reaction of donor-acceptor (D-A) cyclopropanes has emerged as a powerful method for the simple access to useful molecules for materials or biological applications. The ring-opening of the strained substituted cyclopropanes can give easily a 1,3-dipolar intermediate upon thermolysis or under catalysis by Lewis acids[14] which affords formal [2+3]-cycloaddition with alkenes,[15] aldehydes,[16] ketones,[17] isocyanates,[18] imines,[19] diazenes,[20] pyrazolines,[21] azomethine imine ylides,[22] nitrones,[23] acetylenes,[24] nitriles[25] to structure various five-membered carbo- and heterocycles. To the best of our knowledge, no example using 1-cyanocyclopropane 1-ester and pyridine as starting materials to construct the cyanoindolizine core were reported. These products were described as potent central nervous system (CNS) depressant agents, anticancer, anti-inflammatory, and antimalarial agents as shown in Figure 1.[2,5,7] Herein we report a facile and straightforward method to synthesize substituted cyanoindolizines from 1-cyanocyclopropane 1-esters and pyridines via an iodine-catalyzed formal [3+2] cycloaddition reaction.

The starting materials, 2-aroyl-3-aryl-1-cyanocyclopropane carboxylates, were prepared in good yields under mild conditions according to the reported procedure.[26] In order to explore the synthesis of title cyanoindolizines via the [3+2] cycloaddition reactions of substituted cyclopropane with pyridines, the reaction between ethyl 2-(*p*-bromophenyl)-3-(*p*-chlorobenzoyl)-1-cyano cyclopentanecarboxylate and pyridine was chosen as a model reaction to optimize the reaction conditions. The results are summarized in Table 1.



EGFR kinase inhibitor | anticancer | apoptosis inducer | anticonvulsant

Figure 1 Examples of bioactive cyanoindolizines

To start, the reaction was conducted with 1 equiv of ethyl 3-(*p*-bromophenyl)-2-(*p*-chlorobenzoyl)-1-cyanocyclopropane carbonate and 1 equiv of pyridine using a catalytic amount of the Lewis acid $AlCl_3$ $ZnCl_2$, BF_3Et_2O, $FeCl_3$ and I_2 in toluene at 120 °C. As a result, the use of Lewis acid $AlCl_3$ $ZnCl_2$, BF_3Et_2O, or $FeCl_3$ did not produce [3+2] cycloaddition at all (Table 1, entries 1-4). Pleasingly, while molecular iodine was used as a Lewis acid the 3-(*p*-bromophenyl)-2-(*p*-chlorobenzoyl)-1-cyanoindolizine (**2a**) was obtained as the only isolable product in 53% yield (entry 5). When the amount of iodine was increased further to 20 mol%, the reaction was complete after 20 h and the isolated yield was the best 84% (entry 6). The yield was reduced slightly when the amount of iodine was increased from 50 mol % to 200% (entries 7-9). Switching the solvent to DMF decreased the yield to 74% (entry 10). When conducted at 60 °C, the reaction nearly did not take place (entry 11). While the reaction was carried out at 90 °C,

ChemComm Accepted Manuscript

the reaction was incomplete after 20 h and the isolated yield was only 62% (entry 12). Lower yield was obtained when the reaction was conducted at 130-140 °C (entries 13-14). Additionally, the lower yields of **2a** were also observed when this reaction was carried out at 8 - 15 h (entries 15-16), or 24 h (entry 17). A series of experiments revealed that the optimal results were obtained when the reaction of 1-cyanoindolizine **2a** and pyridine together with 20 mol% iodine was carried out in toluene, the resultant mixture was stirred for 20 h at 120 °C, whereby the yield of **2a** reached 84% (Table 1, entry 6).

Table 1 Optimization of reaction conditions in the synthesis of **2a**



Entry	catalyst	solvent	T(°C)	t(h)	yield (%)[a]
1	10% $AlCl_3$	toluene	120	20	0
2	10% $ZnCl_2$	toluene	120	20	0
3	10% BF_3	toluene	120	20	0
4	10% $FeCl_3$	toluene	120	20	0
5	10% I_2	toluene	120	20	53
6	20% I_2	toluene	120	20	84
7	50% I_2	toluene	120	20	78
8	100% I_2	toluene	120	20	73
9	200% I_2	toluene	120	20	71
10	20% I_2	DMF	120	20	74
11	20% I_2	toluene	60	20	9
12	20% I_2	toluene	90	20	62
13	20% I_2	toluene	130	20	74
14	20% I_2	toluene	140	20	64
15	20% I_2	toluene	120	8	26
16	20% I_2	toluene	120	15	54
17	20% I_2	toluene	120	24	83

[a]isolated yield.

Having established the optimal conditions for the synthesis of 1-cyanoindolizine **2a**, to determine the scope of the protocol, a number of available 1-cyano-cyclopropanecarboxylateswere condensed with pyridine or 4-(dimethylamino)pyridine under optimized reaction condition. The results are summarized in Table 2. Both electron-deficient and electron-rich aromatic groups were similarly viable affording the products in moderate to good yields. Pleasingly, simple benzo-fused pyridines (quinoline and isoquinoline) were found to work well, leading to more complex cycloadducts in variable yields. Thus, quinoline and isoquinoline afforded substituted pyrrolo[1,2-*a*]quinoline and pyrrolo[2,1-*a*]isoquinoline in yields of ca 80%, respectively, upon reaction with 1-cyanocyclopropane 1-ester (Table 3 and 4).

Generally, 1-cyanocyclopropane 1-ester with a range of substitutents such as methyl, methoxy, chloro, and bromo at *ortho*-, *meta*- or *para*-positions of phenyl groups all worked well to give 1-cyanoindolizine derivatives. Substrates with *para*-position phenyl groups gave the products in higher yields than those with *ortho*-, or *meta*-position phenyl groups. Besides pyridine and 4-(dimethylamino)pyridine, substrate quinoline and isoquinoline also reacted well with 1-cyanocyclopropane 1-esters to give 1-cyanobenzoindolizine derivatives.

Table 2. Synthesis of cyanoindolizine derivatives from pyridine and 1-cyanocyclopropane 1-ester



Entry	R	R^1	R^2	Yield (%)[a]
1	*p*-Br	*p*-Cl	H	84 (**2a**)
2	*o*-Cl	*p*-Cl	H	79 (**2b**)
3	*p*-CH_3	*p*-Cl	H	81 (**2c**)
4	*m*-Br	H	H	63 (**2d**)
5	*m*-Br	*p*-Cl	H	76 (**2e**)
6	*p*-OCH_3	*p*-Cl	H	80 (**2f**)
7	*o*-Cl	H	H	75 (**2g**)
8	*p*-Br	*p*-Cl	NMe_2	85 (**2h**)
9	*p*-CH_3	*p*-Cl	NMe_2	76 (**2i**)
10	*o*-OCH_3	*p*-Cl	NMe_2	71 (**2j**)
11	*p*-Br	H	NMe_2	84 (**2k**)
12	*p*-Cl	H	NMe_2	82 (**2l**)
13	*m*-Br	H	NMe_2	75 (**2m**)
14	*o*-Cl	H	NMe_2	76 (**2n**)

[a]isolated yield.

Table 3. Synthesis of 1-cyanobenzoindolizine derivatives from isoquinoline and 1-cyanocyclopropane 1-ester



Entry	R	R^1	Yield (%)[a]
1	*p*-Br	H	77 (**3a**)
2	*m*-Br	H	69 (**3b**)
3	*p*-Br	*p*-Br	79 (**3c**)
4	*o*-OCH_3	H	68 (**3d**)

[a]isolated yield.

Table 4. Synthesis of 1-cyanobenzoindolizine derivatives from quinoline and 1-cyanocyclopropane 1-ester



ChemComm Accepted Manuscript

This journal is © The Royal Society of Chemistry [year]

Entry	R	R^1	Yield (%)[a]
1	*o*-CH_3	*p*-Cl	65 (**4a**)
2	*m*-Br	H	64 (**4b**)
3	*p*-CH_3	*p*-Cl	72 (**4c**)

[a]isolated yield.



Figure 2. Molecular structure of 1-cyanoindolizine **2b** and **2h**



Figure 3. Molecular structure of 1-cyanoindolizine **4c**

The structures of **2b**, **2h** and **4c** were shown in Figure 2-3.[27] X-ray crystallographic analysis determined that products **2b**, **2h** and **4c** possess a cyano, an aroyl and an aryl contiguous substituents at C(1), C(2), and C(3). On the basis of spectroscopic evidence the structure of compound **2a-n, 3a-d** and **4a-c** was identified as 3-aryl-2-aroyl-1-cyanoindolizine or 3-aryl-2-aroyl-1-cyanobenzo indolizine.

To test the generality of this new approach for the construction of the cyanoindolizine, the reactions of pyridine as both a substrate and a solvent with selected 1-cyanocyclopropane 1-ester were examined under identical conditions as above (Scheme 1). Interestingly, 3-cyanoindolizine derivatives **5a-n** can be prepared in good yields, respectively (Table 5, entries 1-14), which the result suggested there are different reaction mechanisms for toluene or pyridine as a solvent.



Scheme **1** Synthesis of 3-cyanoindolizine derivatives from 1-cyanocyclopropane 1-ester and pyridine

The structure of **5a** and **5b** were shown in Figure 4.[27] X-ray crystallographic analysis determined that product **5a** and **5b** possess an aryl, an aroyl and a cyano contiguous substituents at C(1), C(2), and C(3). On the basis of spectroscopic evidence the structure of compound **5a-n** was identified as 3-cyano-1-aryl-2-aroylindolizine.

Table 5 Iodine-catalyzed synthesis of 3-cyanoindolizine derivatives

Entry	R^1	R^2	Yield (%)[a]
1	H	*o*-Cl	63 (**5a**)
2	*p*-Br	*p*-Cl	68 (**5b**)
3	H	*o*-Br	52 (**5c**)
4	H	*m*-Br	56 (**5d**)
5	H	*p*-Br	59 (**5e**)
6	H	*o*-CH_3O	82 (**5f**)
7	*p*-Cl	*p*-CH_3O	84 (**5g**)
8	H	*m*-Cl	55 (**5h**)
9	H	*p*-Cl	56 (**5i**)
10	H	*p*-NO_2	73 (**5j**)
11	*p*-CH_3	*p*-Br	77 (**5k**)
12	*o*-CH_3	*p*-Br	51 (**5l**)
13	*p*-Br	*p*-Br	53 (**5m**)
14	*p*-Br	*m*-Cl	58 (**5n**)

[a]isolated yield.



Figure 4. Molecular structure of 3-cyanoindolizine **5a** and **5b**



Scheme 2 Possible mechanism in the synthesis of cyanoindolizines.

On the basis of the above experimental results together with related reports, the reaction mechanism shown in Scheme 2 was proposed. First, under basic conditions, iodine promoted the form of cyclopropane enolate anion [**A**][28] and its conjugation cyclopropyl anion, which was followed by ring opening reaction

ChemComm Accepted Manuscript

on the cyclopropyl anion to generate anion [**B**]. Then, 1,3-dipolar cycloaddition of anion [**B**] as a 1,3-dipole to pyridine gave the enolate anion [**C**]. Further removal of ethyl formate formed dihydroindolizine [**D**].[29] Finally, the dehydroaromatization of dihydroindolizine [**D**] resulted in the formation of the corresponding 1-cyanoindolizidine under air condition in the presence of iodine. Similarly, 3-cyanoindolizidine was obtained because the benzyl anion [**B'**] was a stable resonance in pyridine[30] (Scheme 2). The α-carbon anion of [**B**] with two strongly electrondrawing groups (cyano and ester group) is a stable resonance in a weak polar solvent such as toluene. However, the α-carbon anion of [**B**] possesses larger space steric hindrances and is solvated difficultly by a strong polar solvent (pyridine), it is uneasy to obtain a stable structure in pyridine. On the contrary, [**B'**] with smaller space steric hindrances is solvated easily by pyridine to form a stable resonance structure.

Conclusions

In conclusion, direct annulation of pyridine derivatives with 1-cyanocyclopropane 1-ester to form cyanoindolizine derivatives has been accomplished in a regioselective manner. The reaction proceeds with easily accessible for 1-cyanocyclopropane 1-ester bearing aryl and aroyl groups, and molecular iodine as non-expensive catalyst. Due to the described usefulness of cyanoindolizine derivatives, such simple reaction conditions and functional group tolerance is offering a new attractive method for access to such structures. It is noteworthy that this is the first successful example of iodine-catalyzed one-pot cyclization of a cyanoindolizidine system with 2-aroyl and aryl groups. Therefore, from these results, it can be envisioned that this method will find many applications in organic chemistry and medicinal chemistry.

Acknowledgements

Financial support of this research by the National Natural Science Foundation of China (NNSFC 21173181) is gratefully acknowledged by authors. A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Notes and references

School of Chemistry and Chemical Engineering, Yangzhou University,180 Siwangting Street, Yangzhou 225002, P. R. China. Fax: +86-514-8797-5244; Tel: +86-514-8797-5568; E-mail: wangcd@yzu.edu.cn

† Electronic Supplementary Information (ESI) available: [Reactions conditions and spectra.]. See DOI: 10.1039/b000000x/

1 a) A. Vlahovici, M. Andrei and I. Druta, *J. Lumin.* 2002, **96**, 279; (b) H. Sonnenschein, G. Hennrich, U. Resch-Genger and B. Schulz, *Dyes Pigm.* 2000, **46**, 23; c) E. Kim, M. Koh, B. J. Lim and S. B. Park, *J. Am. Chem. Soc.* 2011, **133**, 6642.

2 a) J. P. Micheal, *Alkaloids Chem. Biol.* 2001, **55**, 91; b) Micheal, J. P. *Nat. Prod. Rep.* 2002, **19**, 742; c) V. L. Pietra, G. L. Regina, A. Coluccia, V. Famiglini, S. Pelliccia, B. Plotkin, H. Eldar-Finkelman, A. Brancale, C. Ballatore, A. Crowe, K. R. Brunden, L. Marinelli, E. Novellino and R. Silvestri, *J. Med. Chem.* 2013, **56**, 10066.

3 W. Lee, R. Gallardo-Macias, K. Frey, K. A. Spasov, M. Bollini, K. S. Anderson, and W. L. Jorgensen, *J. Am. Chem. Soc.* 2013, **135**, 16705.

4 K. Shimizu, M. Iizuka and Y. Takigawa, WO2010113942, 2010.

5 B. Zhao, K. Chen and L. Hu, CN102977098, 2013.

6 G. Bou, E. Santillana, A. Sheri, A. Beceiro, J. Sampson, M. Kalp, C. Bethel, A. Distler, S. Drawz, S. Pagadala, F. Akker, R. Bonomo, A. Romero and J. D. Buynak, *J. Am. Chem. Soc.*, 2010, **132**, 13320.

7 a) B. Francoise, G. Nathalie, M. Jean-Pierre, F. Pierre, O. Jacob-Alsboek and A. Gilles, WO2007080325, 2007; b) W. Kemnitzer, J. Kuemmerle, S. Jiang, H. Zhang, N. Sirisoma, S. Kasibhatla, C. Crogan-Grundy, B. Tseng, J. Drewe and S. Cai, *Bioorg. Med. Chem. Lett*. 2009, **19**, 3481; c) Y. Shen, P. Lv, W. Chen, P. Liu, M. and Zhang, H. Zhu, *Eur. J. Med. Chem.* 2010, **45**, 3184.

8 a) Y. Yang, C. Xie, Y. Xie and Y. Zhang, *Org. Lett*. 2012, **14**, 957; b) R. Bonneau, M. T. H. Liu and R. Lapouyade, *J. Chem. Soc., Perkin Trans. 1*, 1989, 1547.

9 D. Allgäuer, P. Mayer and H. Mayr, *J. Am. Chem. Soc.* 2013, **135**, 15216.

10 a) D. Chernyak, S. Gadamsetty and V. Gevorgyan, *Org. Lett.* 2008, **10**, 2307; b) T. Schwier, A. Sromek, D. Yap, D. Chernyak and V. Gevorgyan, *J. Am. Chem. Soc.* 2007, **129**, 9868.

11 a) B. Viswambharan, K. Selvakumar, S. Madhavan, S. Shanmugam, *Org. Lett.* 2010, **12**, 2108; b) J. Barluenga, G. Lonzi, L. Riesgo, L. A. Lopez and M. Tomas, *J. Am. Chem. Soc.* 2010, **132**, 13200.

12 Y. Li, Z. Zhou, W. Ye, J. Liu, J. Yao and C. Wang, *J. Chem. Res.* 2013, 623.

13 M. Yu and B. L. Pagenkopf, *Tetrahedron* 2005, **61**, 321.

14 H. U. Reissig and R. Zimmer, *Chem. Rev.* 2003, **103**, 1151.

15 a) R. Beal, M. Dombroski and B. Snider, *J. Org. Chem.* 1986, **51**, 4391; b) S. Shimada, Y. Hashimoto, A. Sudo, M. Hasegawa and K. Saigo, *J. Org. Chem.* 1992, **57**, 7126.

16 a) F. Benfatti, F. de Nanteuil and J. Waser, *Org. Lett.* 2012, **14**, 386; b) Y. Bai, W. Tao, J. Ren and Z. Wang, *Angew. Chem., Int. Ed.* 2012, **51**, 4112.

17 a) L. Liu and J. J. Montgomery, *Org. Lett.* 2007, **9**, 3885; b) F. Benfatti, F. de Nanteuil and J. Waser, *Chem. Eur. J.* 2012, **18**, 4844.

18 M. Graziano and M. Iesce, *J. Chem. Res.* 1987, 362.

19 a) C. Carson and M. Kerr, *J. Org. Chem.* 2005, **70**, 8242; b) N. Morra, C. Morales, B. Bajitos, X. Wang, H. Jang, J. Wang, M. Yu and B. Pagenkopf, *Adv. Synth. Catal.* 2006, **348**, 2385.

20 V. Korotkov, O. Larionov, A. Hofmeister, J. Magull and A. de Meijere, *J. Org. Chem.* 2007, **72**, 7504.

21 Y. Tomilov, R. Novikov and O. Nefedov, *Tetrahedron* 2010, **66**, 9151.

22 C. Perreault, S. Goudreau, L. Zimmer, A. Charette, *Org. Lett.* 2008, **10**, 689.

23 a) F. Cardona and A. Goti, *Angew. Chem.* 2005, **117**, 8042; b) M. Sibi, Z. Ma and C. Jasperse, *J. Am. Chem. Soc.* 2005, **127**, 5764; c) M. Ganton and M. Kerr, *J. Org. Chem.* 2004, **69**, 8554.

24 a) V. K. Yadav and V. Sriramurthy, *Org. Lett.* 2004, **6**, 4495; b) V. K. Yadav and V. Sriramurthy, *Angew. Chem.* 2004, **116**, 2723.

25 a) M. Yu and B. L. Pagenkopf, *Org. Lett.* 2001, **3**, 2563; b) M. Yu and B. L. Pagenkopf, *J. Am. Chem. Soc.* 2003, **125**, 2563.

26 a) A. E. Raveendran, R. R. Paul, E. Suresh and V. Nair, *Org. Biomole. Chem.* 2010, **8**, 901; b) V. Rama, K. Kanagaraj, T. Subramanian, P. Suresh and K. Pitchumani, *Catal. Commun.* 2012, **26**, 39; c) Q. Wang, X. Song, J. Chen and C. Yan, *J. Combi. Chem.* 2009, **11**, 1007.

27 Crystallographic data for **2b**, **2h**, **4c**, **5a** and **5b** have been deposited with the Cambridge Crystallographic Data Centre with the deposition number CCDC 978204, 978827, 970814, 939543 and 939542. These data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax (+44) 1223 336033, e-mail: deposit@ccdc.cam.ac.uk].

28 a) D. Bandyopadhyay, J. Cruz, R. N. Yadav and B. K. Banik, *Molecules* 2012, **17**, 11570; b) G. Ramachandran and K. I. Sathiyanarayanan, *Tetrahedron Lett*, 2013, **54**, 6758.

29 a) I. Hogan, P. D. Jenkins and M. Sainsbury,*Tetrahedron*, 1990, **46**, 2943; b) S. Gowrisankar, D. Y. Park and J. N. Kim, *Bull. Korean Chem. Soc.* 2005, **26**, 1826.

30 C. Reichardt, Solvents and Solvent Effects in Organic Chemistry, 3rd edit. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2003.

ChemComm Accepted Manuscript

This journal is © The Royal Society of Chemistry [year]